An interventional study of Carotid Revascularization and Medical Treatment in Carotid Artery Stenting, Carotid Endarterectomy and Best Medical Treatment, sponsored by Xuanwu Hospital, Beijing. Recruiting at 11 sites in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-01-31.
Sponsored by Xuanwu Hospital, Beijing · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Carotid Stenosis by Xuanwu Hospital, Beijing — 5 open to participants now, 6 under way, none of them phase 3. Carotid Stenosis · Xuanwu Hospital, Beijing.
Among the 11 studies in Carotid Stenosis by Xuanwu Hospital, Beijing, this one is one of 3 that started in 2022, is one of 5 with no phase, and was the 7th registered.
369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.
Browse Carotid Stenosis studies →5 of the 11 studies in Carotid Stenosis by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:
Xuanwu Hospital, Beijing · Sites in China
Ages 45–80
Xuanwu Hospital, Beijing · Sites in China
Ages 18+
Xuanwu Hospital, Beijing · Sites in China
Ages 18–80
Xuanwu Hospital, Beijing · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2022.
This study's planned enrollment of 1,056 is above the median of 102 across 192 interventional studies indexed under Carotid Stenosis.
Median enrollment 500 across the 5 interventional studies, 600 across the 6 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Xuanwu Hospital, Beijing is the lead sponsor of 365 studies on the registry; 231 are open to participants now.
1 of the studies in Carotid Stenosis by Xuanwu Hospital, Beijing that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05134246Xuanwu Hospital, BeijingCarotid Revascularization for Radiation Induced Carotid Artery Stenosis | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Carotid Stenosis by Xuanwu Hospital, Beijing, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open, randomized controlled trial to evaluate the efficacy and safety of carotid artery stenting/carotid endarterectomy versus best medical treatment for asymptomatic carotid artery stenosis in Chinese population.
This is a multicenter, open, randomized controlled trial to evaluate the efficacy and safety of carotid artery stenting/carotid endarterectomy versus best medical treatment for asymptomatic carotid artery stenosis in Chinese population. The study will be conducted at 11 centers and is expected to enroll 1056 patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Carotid Artery Stenting/Carotid endarterectomy + Best Medical Treatment
Procedure: Carotid Revascularization · Drug: Medical Treatment
Best Medical Treatment
Drug: Medical Treatment
Carotid Artery Stenting/Carotid Endarterectomy
Aspirin 100mg/ day plus clopidogrel 75mg/ day for the first three months after enrollment or revascularization, aspirin 100mg/ day after three months, and the statin dose was adjusted according to blood lipids levels. Best medical treatment also includes risk factor control: good lifestyle, smoking cessation, weight control, regular exercise, SBP \< 140 mmHg, HDL \< 70 mg/dl (1.8mmol/L), and glycemic control. Patients with poor control of risk factors were dynamically adjusted during follow-up. In addition, patients undergoing CAS received dual antiplatelet therapy for at least 3 to 5 days before surgery, and patients undergoing CEA also received a preoperative oral antiplatelet drug (aspirin 100mg/ day, or clopidogrel 75mg/ day) for at least 3 days after enrollment.
Any Periprocedural Stroke, Myocardial Infarction, or Death During1 month Peri-procedural Period, and Postprocedural Ipsilateral Stroke 1 to 12-months.
Composite of any periprocedural stroke (ipsilateral or contralateral; major or minor), myocardial infarction, or death during1 month peri-procedural period, and postprocedural ipsilateral stroke 1 to 12-months.
Time frame: 0 to 12 months
Technical success rate
Technical success was defined as final residual stenosis less than 30%, TIMI grade 3, and no dissection or thrombus after any endovascular treatment.
Time frame: 1 day
Rate of complications
Rate of complications within 30 days, complications include:Cranial nerve and peripheral nerve injury, vascular injury, non cerebral hemorrhage, wound complications as neck incision or related to puncture site, and other (such as anesthesia) complications.
Time frame: 30 days
Incidence of myocardial infarction
Incidence of myocardial infarction at 30 days follow up.
Time frame: 30 days
Incidence of ipsilateral stroke
Incidence of ipsilateral stroke at 30 days follow up.
Time frame: 30 days
Incidence of death
Incidence of death at 30 days follow up.
Time frame: 30 days
Carotid restenosis rate
Carotid restenosis was defined as restenosis ≥50% after carotid revascularization, that is, peak systolic velocity ratio (PSVR) ≥2.0 on ultrasound examination.
Time frame: 12 months
Incidence of target lesion revascularization
Target lesion revascularization (TLR) is defined as the re-percutaneous intervention or bypass grafting of the target lesion for restenosis or other complications of the target lesion. All TLR should be preclassified as clinically drived or non-clinically drived before the investigator performs angiography again.
Time frame: 12 months
Improvement in cognitive function
Cognitive function was assessed by Montreal Cognitive Assessment Scale (MoCA) at 30 days follow up.
Time frame: 30 days
Improvement in cognitive function
Cognitive function was assessed by Mini-mental State Examination (MMSE) at 30 days follow up.
Time frame: 30 days
Improvement in cognitive function
Cognitive function was assessed by Montreal Cognitive Assessment Scale (MoCA) at 12 months follow up.
Time frame: 12 months
Improvement in cognitive function
Cognitive function was assessed by Mini-mental State Examination (MMSE) at 12 months follow up.
Time frame: 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2022 (actual). Primary completion is estimated for Dec 2025, 38 months after the start.
Of 51 non-industry interventional studies with no phase under Carotid Stenosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 50. This study's planned 38 months is above that.
Counting every sponsor, half of 62 studies reached it within 27 months; a quarter within 19 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.